Essity AB (publ) ESSITY-B.ST
Composite 58/100; the shares have moved about 19% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 34/100 — a moderate mark against it.
Income ranks 77/100 — a strong point in its favour. Balance-sheet strength ranks 67/100 — a moderate point in its favour. Valuation ranks 61/100 — a slight point in its favour.
Growth ranks 34/100 — a moderate mark against it.
What the company does Essity AB develops, produces, and sells hygiene and health products and services globally across Health & Medical, Consumer Goods, and Professional Hygiene segments. Brands include TENA, Libero, Tempo, and Leukoplast, distributed through retail, e-commerce, and healthcare channels.
Key financials Essity reports ROE 14%, ROA 6.6%, and ROCE 14.3%, with gross margins 33.3% and net margins 8.8%. Revenue grew 2.6% while EPS declined -10.3%. Debt/Equity is 0.46 and interest coverage is 16.24x.
Stock health Sideravia scores Valuation 60.9 and Momentum 67.8, with overall quality at 59.0. The stock shows strong 12-month momentum at 17.99% and RSI(14) at 54.70, indicating neutral momentum.
Price vs fair value The stock trades at a PREMIUM of 24.30% versus our fair-value estimate and a PREMIUM of 2.76% versus the 12-month analyst target. - Fair-value premium of 24.30% reflects valuation multiples above historical averages (Valuation 60.9 percentile). - Analyst target premium of 2.76% suggests limited upside from current levels despite positive momentum. - Dividend yield of 3.1% and payout ratio 49.4% support income appeal (Income 81.7 percentile). - Net margins at 8.8% lag peers, constraining valuation expansion.
Looking forward Forward P/E of 15.20 and PEG of 3.83 imply moderate growth expectations. Analysts expect stability, but margin recovery and growth acceleration are key to closing the valuation gap.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.